This Monday may well mark a fundamental change in our society. A huge claim, but bear with me. For the first time, weight-loss pills containing semaglutide – the active ingredient that transformed obesity treatment through injectable drugs such as Ozempic – will be available in pill form through UK pharmacies and online providers. The level of interest has been described as “significant” by the pharmacy industry, with tens of thousands registering their interest.
This is not simply the launch of another medicine. It is potentially the start of a profound shift in how Britain thinks about weight, health and personal responsibility. The implications stretch beyond medicine cabinets and GP surgeries. They could reshape everything from supermarkets and restaurants to pubs, gyms, employers and, ultimately, the NHS.
For decades, wanting to lose weight has come entailed familiar advice: eat less, move more. That message has clearly failed. Almost one in three UK adults now lives with obesity, while excess weight contributes to conditions ranging from type 2 diabetes to heart disease. The NHS spends billions every year treating obesity-related illness.
Drugs such as Wegovy, Mounjaro and Ozempic have already begun rewriting that story. In the United States, GLP-1 medicines have generated extraordinary demand. Analysts predict the market could be worth more than $100bn globally within a decade. But injections, however effective, have always represented a psychological hurdle. Many people simply do not want to inject themselves.
